Preoperative chemoradiation with raltitrexed ('Tomudex') for T2/N+ and T3/N+ rectal cancers: a phase I study. Valentini V1, Doglietto GB, Morganti AG, Turriziani A, Smaniotto D, De Santis M, Ratto C, Sofo L, Cellini N. Author information Abstract The use of raltitrexed ('Tomudex') as concomitant chemotherapy during preoperative radiotherapy in chemonaïve patients with stage II/III rectal cancer has been examined in this study and its recommended dose in conjunction with radiotherapy investigated. Forty-five Gray (Gy) of radiotherapy (1.8 Gy daily, 5 days per week) was delivered to the posterior pelvis, followed by a 5.4 Gy boost. Single doses of raltitrexed (2.0, 2.5 and 3.0 mg/m(2)) were administered on days 1, 19 and 38. Only 1 of the 15 patients entered experienced a dose limiting toxicity (DLT) (grade 3 leucopenia) at the 3.0 mg/m(2) dose level. The overall response rate was 80% (five complete responses, seven partial responses). These preliminary data suggest that raltitrexed is a well tolerated and effective treatment when combined with preoperative radiotherapy in patients with stage II/III rectal cancer. The recommended dose of raltitrexed for future phase II studies will be 3.0 mg/m(2). PMID: 11597383 [PubMed - indexed for MEDLINE]

Valentini, V., Doglietto, G., Morganti, A. G., Turriziani, A., Smaniotto, D., De Santis, M., Ratto, C., Sofo, L., Cellini, N., Preoperative chemoradiation with raltitrexed (Tomudex) in T2/N+ and T3/N+ rectal cancers: a phase I study., <<EUROPEAN JOURNAL OF CANCER>>, 2001; (37): 2050-2055 [http://hdl.handle.net/10807/65830]

Preoperative chemoradiation with raltitrexed (Tomudex) in T2/N+ and T3/N+ rectal cancers: a phase I study.

Valentini, Vincenzo;Doglietto, Giovanni;Morganti, Alessio Giuseppe;Smaniotto, Daniela;
2001

Abstract

Preoperative chemoradiation with raltitrexed ('Tomudex') for T2/N+ and T3/N+ rectal cancers: a phase I study. Valentini V1, Doglietto GB, Morganti AG, Turriziani A, Smaniotto D, De Santis M, Ratto C, Sofo L, Cellini N. Author information Abstract The use of raltitrexed ('Tomudex') as concomitant chemotherapy during preoperative radiotherapy in chemonaïve patients with stage II/III rectal cancer has been examined in this study and its recommended dose in conjunction with radiotherapy investigated. Forty-five Gray (Gy) of radiotherapy (1.8 Gy daily, 5 days per week) was delivered to the posterior pelvis, followed by a 5.4 Gy boost. Single doses of raltitrexed (2.0, 2.5 and 3.0 mg/m(2)) were administered on days 1, 19 and 38. Only 1 of the 15 patients entered experienced a dose limiting toxicity (DLT) (grade 3 leucopenia) at the 3.0 mg/m(2) dose level. The overall response rate was 80% (five complete responses, seven partial responses). These preliminary data suggest that raltitrexed is a well tolerated and effective treatment when combined with preoperative radiotherapy in patients with stage II/III rectal cancer. The recommended dose of raltitrexed for future phase II studies will be 3.0 mg/m(2). PMID: 11597383 [PubMed - indexed for MEDLINE]
Inglese
Valentini, V., Doglietto, G., Morganti, A. G., Turriziani, A., Smaniotto, D., De Santis, M., Ratto, C., Sofo, L., Cellini, N., Preoperative chemoradiation with raltitrexed (Tomudex) in T2/N+ and T3/N+ rectal cancers: a phase I study., <>, 2001; (37): 2050-2055 [http://hdl.handle.net/10807/65830]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/65830
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 17
social impact